Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

PHASE3TerminatedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

March 28, 2022

Study Completion Date

March 28, 2022

Conditions
Osteogenesis Imperfecta (OI)
Interventions
DRUG

Denosumab

Solution for injection

DRUG

Alternative osteoporosis medications

Alternative osteoporosis medication/s at the discretion of the investigator.

Trial Locations (22)

1094

Semmelweis Egyetem, Budapest

1200

Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Brussels

2145

The Childrens Hospital at Westmead, Westmead

6909

Perth Childrens Hospital, Nedlands

33076

Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin, Bordeaux

46026

Hospital Universitari i Politecnic La Fe, Valencia

46202

Indiana University - Riley Hospital for Children, Indianapolis

50931

Uniklinik Köln, Cologne

75743

Hopital Necker Enfants Malades, Paris

90027

Childrens Hospital of Los Angeles, Los Angeles

K1H 8L1

Childrens Hospital of Eastern Ontario, Ottawa

M5G 1X8

The Hospital for Sick Children, Toronto

H4A 0A9

Shriners Hospital for Children, Montreal

305 99

Fakultni nemocnice Plzen, Pilsen

140 59

Thomayerova nemocnice, Prague

00161

Azienda Ospedaliera Policlinico Umberto I, Roma

91-738

SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Lodz

08950

Hospital Sant Joan de Deu, Esplugues de Llobregat

B4 6NH

Birmingham Childrens Hospital, Birmingham

BS2 8AE

Bristol Royal Hospital for Children, Bristol

G51 4TF

Royal Hospital for Children, Glasgow

S10 2TH

Sheffield Childrens Hospital, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY